Memo Therapeutics plots Phase 3 trial for kidney infection drug despite mid-stage study miss

Memo Therapeutics said Friday it is planning to advance its monoclonal antibody for kidney transplant patients with a viral infection into Phase 3 even though the drug didn’t pass a mid-stage test. The candidate, known ...